Long-Term Follow Up After Third Party Viral-Specific Cytotoxic Lymphocytes For Immunosuppression- And Epstein-Barr Virus-Associated Lymphoproliferative Disease

Sajida Kazi; Abhinav Mathur; Gwen Wilkie; Kirsty Cheal; Richard Battle; Neil McGowan; Neil Fraser; Emily Hargreaves; David Turner; John D. M. Campbell; Marc Turner; Mark A. Vickers

doi:10.3324/haematol.2018.207548

Long-Term Follow Up After Third Party Viral-Specific Cytotoxic Lymphocytes For Immunosuppression- And Epstein-Barr Virus-Associated Lymphoproliferative Disease

Sajida Kazi, Abhinav Mathur, Gwen Wilkie, Kirsty Cheal, Richard Battle, Neil McGowan, Neil Fraser, Emily Hargreaves, David Turner, John D. M. Campbell, Marc Turner, Mark A. Vickers (Corresponding Author)

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

Epstein-Barr virus (EBV)-associated lymphoproliferative disease is a serious complication of immunosuppression, particularly after transplantation. Treatment by reduction of immunosuppression risks graft loss after solid organ transplantation (SOT) and only 25-50% of patients respond.

Original language	English
Pages (from-to)	e356-e359
Number of pages	4
Journal	Haematologica
Volume	104
Issue number	8
Early online date	21 Feb 2019
DOIs	https://doi.org/10.3324/haematol.2018.207548
Publication status	Published - Aug 2019

Keywords

T-CELL THERAPY
DISORDER
RISK
MANAGEMENT
RECIPIENTS

Access to Document

10.3324/haematol.2018.207548Licence: Other

Cite this

Kazi, S., Mathur, A., Wilkie, G., Cheal, K., Battle, R., McGowan, N., Fraser, N., Hargreaves, E., Turner, D., Campbell, J. D. M., Turner, M., & Vickers, M. A. (2019). Long-Term Follow Up After Third Party Viral-Specific Cytotoxic Lymphocytes For Immunosuppression- And Epstein-Barr Virus-Associated Lymphoproliferative Disease. Haematologica, 104(8), e356-e359. https://doi.org/10.3324/haematol.2018.207548

Kazi, S, Mathur, A, Wilkie, G, Cheal, K, Battle, R, McGowan, N, Fraser, N, Hargreaves, E, Turner, D, Campbell, JDM, Turner, M & Vickers, MA 2019, 'Long-Term Follow Up After Third Party Viral-Specific Cytotoxic Lymphocytes For Immunosuppression- And Epstein-Barr Virus-Associated Lymphoproliferative Disease', Haematologica, vol. 104, no. 8, pp. e356-e359. https://doi.org/10.3324/haematol.2018.207548

@article{ad75936d02a647d7a8e2f0881f70240d,

title = "Long-Term Follow Up After Third Party Viral-Specific Cytotoxic Lymphocytes For Immunosuppression- And Epstein-Barr Virus-Associated Lymphoproliferative Disease",

abstract = "Epstein-Barr virus (EBV)-associated lymphoproliferative disease is a serious complication of immunosuppression, particularly after transplantation. Treatment by reduction of immunosuppression risks graft loss after solid organ transplantation (SOT) and only 25-50% of patients respond.",

keywords = "T-CELL THERAPY, DISORDER, RISK, MANAGEMENT, RECIPIENTS",

author = "Sajida Kazi and Abhinav Mathur and Gwen Wilkie and Kirsty Cheal and Richard Battle and Neil McGowan and Neil Fraser and Emily Hargreaves and David Turner and Campbell, {John D. M.} and Marc Turner and Vickers, {Mark A.}",

note = "The authors would like to thank the Wellcome Trust for funding the initial set up of this bank, and the blood donors from New Zealand who provided cells.",

year = "2019",

month = aug,

doi = "10.3324/haematol.2018.207548",

language = "English",

volume = "104",

pages = "e356--e359",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "8",

}

TY - JOUR

T1 - Long-Term Follow Up After Third Party Viral-Specific Cytotoxic Lymphocytes For Immunosuppression- And Epstein-Barr Virus-Associated Lymphoproliferative Disease

AU - Kazi, Sajida

AU - Mathur, Abhinav

AU - Wilkie, Gwen

AU - Cheal, Kirsty

AU - Battle, Richard

AU - McGowan, Neil

AU - Fraser, Neil

AU - Hargreaves, Emily

AU - Turner, David

AU - Campbell, John D. M.

AU - Turner, Marc

AU - Vickers, Mark A.

N1 - The authors would like to thank the Wellcome Trust for funding the initial set up of this bank, and the blood donors from New Zealand who provided cells.

PY - 2019/8

Y1 - 2019/8

N2 - Epstein-Barr virus (EBV)-associated lymphoproliferative disease is a serious complication of immunosuppression, particularly after transplantation. Treatment by reduction of immunosuppression risks graft loss after solid organ transplantation (SOT) and only 25-50% of patients respond.

AB - Epstein-Barr virus (EBV)-associated lymphoproliferative disease is a serious complication of immunosuppression, particularly after transplantation. Treatment by reduction of immunosuppression risks graft loss after solid organ transplantation (SOT) and only 25-50% of patients respond.

KW - T-CELL THERAPY

KW - DISORDER

KW - RISK

KW - MANAGEMENT

KW - RECIPIENTS

UR - http://www.mendeley.com/research/longterm-follow-up-after-third-party-viralspecific-cytotoxic-lymphocytes-immunosuppression-epsteinba

UR - http://www.scopus.com/inward/record.url?scp=85070582249&partnerID=8YFLogxK

U2 - 10.3324/haematol.2018.207548

DO - 10.3324/haematol.2018.207548

M3 - Article

C2 - 30792197

VL - 104

SP - e356-e359

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 8

ER -

Long-Term Follow Up After Third Party Viral-Specific Cytotoxic Lymphocytes For Immunosuppression- And Epstein-Barr Virus-Associated Lymphoproliferative Disease

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this